Core Viewpoint - The stock of HeFu China (603122) experienced significant volatility, with a cumulative increase of 256.29% over a period of 14 trading days, leading to a temporary suspension of trading for verification due to abnormal price fluctuations [1][2] Group 1: Stock Performance and Trading Suspension - HeFu China announced the completion of a trading suspension verification, with the stock set to resume trading on November 20, 2025 [1] - The stock hit the daily limit up on 12 out of 14 trading days, with five instances of abnormal fluctuations and three instances of severe fluctuations [1] - The company’s stock price is currently significantly higher than its operational performance and industry conditions, indicating a potential disconnect [1][2] Group 2: Financial Performance and Valuation - As of November 14, 2025, HeFu China's static price-to-earnings (P/E) ratio was 343.67, compared to the industry average of 30.94, suggesting a bubble in the stock price [2] - The company reported a net loss of 5.048 million yuan in Q3 2025, a year-on-year decline of 225.26%, attributed to changes in the macroeconomic environment and price reductions in the medical industry [2] - Despite implementing cost control measures, the company faces pressure on its short-term operating performance due to declining sales revenue and profit levels [2]

证券时报记者严翠 11月19日晚，合富中国停牌核查迎来进展。该公司公告，近期，公司就股票交易异常波动及严重异常波 动的相关事项进行了核查。鉴于相关核查工作已完成，经公司向上交所申请，公司股票将复牌。 合富中国表示，经公司自查，公司目前日常经营活动一切正常，公司内外部经营环境未发生重大变化， 公司未发现其他有可能对公司股价产生较大影响的重大事件，公司董事、高级管理人员、控股股东及间 接控股股东在公司本次股票交易异常波动期间不存在买卖公司股票的情况。 合富中国称，公司最新市盈率水平显著高于同行业上市公司水平，当前股价存在明显泡沫化特征。截至 2025年11月14日，公司静态市盈率为343.67倍，根据同日中证指数有限公司网站发布的行业数据，公司 所属的批发业的行业静态市盈率为30.94倍，存在公司股价严重偏离同行业上市公司合理估值的风险。 本次股价连续上涨期间，公司股票流通换手率亦出现较大波动情形，击鼓传花效应明显，请广大投资者 注意甄别、理性判断。 另外，基本面方面，合富中国称，目前公司仍处于亏损状态，公司2025年第三季度净利润为-504.8万 元，同比下降225.26%，主要系受国内宏观形势变动，以及集中采 ...

11月14日，合富中国（603122）(603122.SH)发布公告，因公司股票在2025年10月28日至11月14日期间连续十四个交易日中有十二个交易日以涨停价收 盘，累计涨幅达256.29%，已多次触及股价异常波动及严重异常波动情形，且股价涨幅明显偏离公司基本面和行业水平，存在市场情绪过热、非理性炒作 风险。为维护投资者利益，经申请，公司股票自2025年11月17日开市起停牌，预计停牌时间不超过3个交易日，待披露核查公告后复牌。 公司提醒投资者注意二级市场交易风险，当前市盈率显著高于行业平均水平，经营业绩承压，2025年第三季度净利润为-504.8万元，同比下滑225.26%， 股价与经营情况严重偏离，敬请理性投资，审慎决策。 此前，多家券商披露，上海证券交易所已明确指出，"合富中国"等股票的交易情况已构成严重异常波动。后续，交易所将对其异常交易行为从严认定，并 视情况从重采取列为重点监控账户、暂停投资者账户交易、限制投资者账户交易等自律管理措施。 对于业绩亏损情况，合富中国解释，利润变动主要受集中采购降价等医疗行业政策调整的影响，公司面向医院客户的产品采购单价有所下调，叠加同期订 单采购量较上年出现缩减 ...

Core Viewpoint - 合富中国 (603122) has experienced significant stock price volatility, leading to a suspension of trading for verification due to a 256.29% increase in stock price over a short period, which is substantially higher than the industry and Shanghai Composite Index performance [1][2] Group 1: Stock Performance and Trading Suspension - 合富中国's stock has hit the daily limit up on 12 out of 14 trading days, with 5 instances of abnormal price fluctuations and 3 instances of severe fluctuations [1] - The stock will be suspended from trading starting November 17, 2025, for a period not exceeding 3 trading days [2] - As of November 14, 2025, the stock closed at 23.8 yuan per share, with a total market capitalization of 9.5 billion yuan [2] Group 2: Financial Performance - The third quarter report indicates a year-on-year decline in revenue, with a total revenue of 181 million yuan, representing a decrease of 21.27% [3][4] - The company reported a net loss attributable to shareholders of 5.05 million yuan for the third quarter, a significant decline of 225.26% compared to the previous year [4] - The decline in revenue and profit is attributed to changes in the domestic macroeconomic environment and price reductions in the medical industry due to centralized procurement policies [4] Group 3: Valuation Concerns - 合富中国's current price-to-earnings (P/E) ratio stands at 343.67, significantly higher than the industry average P/E ratio of 30.94 for wholesale industry companies [5] - The company has indicated that the stock price shows signs of being in a bubble, with trading volume fluctuations suggesting a "hot potato" effect [5] - Investors are advised to be cautious of the company's performance volatility and high valuation risks, and to make rational investment decisions [5]

Core Viewpoint - The stock of HeFu China has experienced a significant increase, with a cumulative rise of 256.29% over a period of 14 trading days, raising concerns about market overheating and irrational speculation [1][3]. Company Performance - HeFu China's third-quarter report indicates a year-on-year decline in revenue, with total revenue of 181 million yuan, down 21.27%, and a net profit attributable to shareholders of -5.05 million yuan, reflecting a 225.26% decrease compared to the previous year [4][5]. - The company has faced challenges due to changes in the domestic macroeconomic environment and price reductions in medical industry policies, leading to a decrease in sales revenue and profit levels [5][6]. Stock Market Activity - The stock will be suspended from trading starting November 17, 2025, for a period not exceeding three trading days, following the announcement of the stock price fluctuations [2][3]. - As of November 14, 2025, the stock's static price-to-earnings ratio is 343.67 times, significantly higher than the industry average of 30.94 times, indicating a potential overvaluation [6][7]. Investor Advisory - The company has warned investors about the risks associated with performance volatility and high valuation, urging them to make rational decisions and be cautious of market sentiment [7].

Group 1 - The stock of HeFu China (603122) has hit the daily limit up for seven consecutive trading days, currently priced at 13.04 yuan per share with over 200,000 hands on the limit up board [1] - The company issued a risk warning stating that its main business has not undergone significant changes, and the recent stock price surge may be due to overheated market sentiment and irrational speculation, significantly deviating from the company's fundamentals [1] - The company's current price-to-earnings (P/E) ratio is 171.11 times, which is substantially higher than the industry average P/E ratio of 28.90 times, indicating a risk of severe deviation from reasonable valuations [1] Group 2 - In Q3 2025, the company reported a net profit attributable to shareholders of -5.048 million yuan, a decline of 225.26% year-on-year, primarily due to changes in the domestic macroeconomic environment and price reductions from centralized procurement policies in the medical industry [2] - The decrease in product procurement prices for hospital clients, along with a reduction in order volumes compared to the previous year, has led to a decline in both sales revenue and profit levels [2] - Although the company has implemented several cost control measures, the short-term reduction in expenses has not fully offset the decline in revenue, resulting in pressure on short-term operating performance and potential earnings volatility [2]